224 results on '"Pallansch, Mark A."'
Search Results
2. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences
3. Worst‐case scenarios: Modeling uncontrolled type 2 polio transmission
4. Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial
5. Assessing country compliance with circulating vaccine-derived poliovirus type 2 outbreak response standard operating procedures: April 2016 to December 2020
6. Circulating Poliovirus in New York — New Instance of an Old Problem
7. Outbreak response strategies with type 2-containing oral poliovirus vaccines
8. Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal
9. Enteroviruses and Parechoviruses
10. Standardized Methods for Detection of Poliovirus Antibodies
11. Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial
12. The Mechanism of Poliovirus Eradication
13. Epidemiology
14. Modeling Poliovirus Surveillance and Immunization Campaign Quality Monitoring Costs for Pakistan and Afghanistan for 2019–2023
15. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response
16. Updated Characterization of Poliovirus Transmission in Pakistan and Afghanistan and the Impacts of Different Outbreak Response Vaccine Options
17. The impact of disruptions caused by the COVID-19 pandemic on global polio eradication
18. Updated Characterization of Outbreak Response Strategies for 2019–2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain
19. Certifying the interruption of wild poliovirus transmission in the WHO African region on the turbulent journey to a polio-free world
20. Enterovirus Infections, Including Poliomyelitis
21. Contributors
22. Progress Toward Poliovirus Containment Implementation — Worldwide, 2019–2020
23. Updated Characterization of Post‐OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart
24. The Long and Winding Road to Eradicate Vaccine-Related Polioviruses
25. Modeling Poliovirus Transmission in Borno and Yobe, Northeast Nigeria
26. First Case of 2019 Novel Coronavirus in the United States
27. Neutralization capacity of highly divergent type 2 vaccine-derived polioviruses from immunodeficient patients
28. Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame
29. Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2018–June 2019
30. Acute Flaccid Myelitis in the United States: 2015–2017
31. Enterovirus Infections, Including Poliomyelitis
32. Molecular Detection and Characterization of Human Enteroviruses
33. Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial
34. Characterising the costs of the Global Polio Laboratory Network: a survey-based analysis
35. Increase in Acute Flaccid Myelitis — United States, 2018
36. Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses
37. Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Pakistan and Afghanistan
38. Molecular Epidemiology of Wild Poliovirus Transmission
39. Breaking the Last Chains of Poliovirus Transmission: Progress and Challenges in Global Polio Eradication
40. Ending Use of Oral Poliovirus Vaccine — A Difficult Move in the Polio Endgame
41. Progress in Vaccine-Preventable and Respiratory Infectious Diseases—First 10 Years of the CDC National Center for Immunization and Respiratory Diseases, 2006–2015
42. Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial
43. Acute Flaccid Myelitis - Epidemiology and Clinical Characteristics, United States, August 2014 – August 2017 (P6.421)
44. The seasonality of nonpolio enteroviruses in the United States: Patterns and drivers
45. Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations
46. The role of supplementary environmental surveillance to complement acute flaccid paralysis surveillance for wild poliovirus in Pakistan – 2011–2013
47. Insights from a Systematic Search for Information on Designs, Costs, and Effectiveness of Poliovirus Environmental Surveillance Systems
48. The Global Polio Laboratory Network as a Platform for the Viral Vaccine-Preventable and Emerging Diseases Laboratory Networks
49. Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule
50. Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.